GSK (LON:GSK) Reaches New 12-Month Low - Should You Sell?

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GSK was reported to have hit a new 52-week low, while shares were last quoted at GBX 1,852.50. Its 50-day average was GBX 1,851.56, below its 200-day average of GBX 1,952.01.
  • Analysts’ consensus rating is Hold, with an average price target of GBX 2,145; three analysts rate the stock Buy, four Hold, and one Sell.
  • GSK reported quarterly EPS of GBX 54.60 and revenue of GBX 888.70 billion. Insiders also purchased a total of 2,151 shares over the past 90 days.
  • Interested in GSK? Here are five stocks we like better.

GSK plc (LON:GSK - Get Free Report)'s stock price reached a new 52-week low during trading on Friday. The company traded as low as GBX 18.50 and last traded at GBX 1,852.50, with a volume of 199,092,344 shares. The stock had previously closed at GBX 1,827.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. Berenberg Bank reissued a "buy" rating and issued a GBX 2,200 target price on shares of GSK in a report on Tuesday, November 3rd. Royal Bank Of Canada began coverage on GSK in a report on Tuesday, September 8th. They set a "sector perform" rating and a GBX 1,975 target price on the stock. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Finally, Deutsche Bank reissued a "hold" rating and issued a GBX 2,000 price target on shares of GSK in a research report on Tuesday, November 10th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of GBX 2,145.

Read Our Latest Stock Report on GSK

GSK Price Performance

The company has a market cap of £74.29 billion, a price-to-earnings ratio of 17.33, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28. The company has a fifty day moving average price of GBX 1,851.56 and a two-hundred day moving average price of GBX 1,952.01. The company has a current ratio of 0.86, a quick ratio of 0.73 and a debt-to-equity ratio of 126.38.

GSK (LON:GSK - Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. The business had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. As a group, equities research analysts anticipate that GSK plc will post 175.98 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Anne Beal bought 637 shares of the firm's stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business's stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders bought a total of 2,151 shares of company stock worth $6,021,921 over the last 90 days. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines